Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis
Netakimab, the original monoclonal antibody against IL-17A, is an innovative drug for the treatment of moderate-to-severe plaque psoriasis in patients who have indications for systemic therapy or phototherapy. Netakimab was approved in Russian Federation, registration certificate number ЛП-005439 fr...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
State Scientific Center of Dermatovenereology and Cosmetology
2019-07-01
|
| Series: | Vestnik Dermatologii i Venerologii |
| Subjects: | |
| Online Access: | https://www.vestnikdv.ru/jour/article/view/480 |